About Vanda Pharmaceuticals Inc. - Common Stock (VNDA)
Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs in the fields of central nervous system disorders and sleep disorders. The company is dedicated to improving the lives of patients through its specialized drug products, which aim to treat conditions such as schizophrenia and insomnia. Vanda's research and development efforts are primarily geared towards advancing its pipeline of proprietary medicine, leveraging scientific expertise and clinical insight to enhance treatment options for patients around the world. Read More
Vanda Pharma's Q3 2025 results show a revenue miss but a smaller-than-expected loss. The stock fell as strong Fanapt sales growth was offset by investor focus on the top-line shortfall.
The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety.
WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP).
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws.
